Treats relapsing forms of multiple sclerosis (MS). ANDA 208468, held by Chemi Spa. Glatiramer Acetate.
As of Nov 16, 2026, ANDA 208468 (Glatiramer Acetate), held by Chemi Spa, was first approved by FDA on May 7, 2025, with 0 approved supplements and 0 published complete response letters.
Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 7, 2025 | Original application | Approved | None posted |
| Glatiramer Acetate20MG/ML · injectable;subcutaneous | Glatiramer Acetate | Rx |
| Glatiramer Acetate40MG/ML · injectable;subcutaneous | Glatiramer Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters